A Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Subjects With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 31 May 2019
Price : $35 *
At a glance
- Drugs Ibrutinib (Primary)
- Indications Graft-versus-host disease
- Focus Registrational; Therapeutic Use
- Sponsors Janssen Pharmaceutical KK
- 28 May 2019 Status changed from recruiting to active, no longer recruiting.
- 29 Apr 2019 Planned End Date changed from 31 Dec 2022 to 30 Jun 2022.
- 23 May 2018 Status changed from not yet recruiting to recruiting.